267901-75-7

Upstream product

• 637-44-5 phenylpropyolic acid 
• 7463-51-6 4-bromo-3,5-dimethylphenol 
• 267901-42-8 4-bromo-3,-5-dimethyl-phenyl 3-phenylpropiolate 

Downstream Products

• 1428553-75-6 5,7-dimethyl-6-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-4-phenyl-2H-chromen-2-one 
• 1428553-87-0 6-(4-(hydroxymethyl)-2-methylphenyl)-5,7-dimethyl-4-phenyl-2H-chromen-2-one 
• 1428553-98-3 4-(5,7-dimethyl-2-oxo-4-phenyl-2H-chromen-6-yl)-N-methylbenzamide 
• 1428554-05-5 5,7-dimethyl-4-phenyl-6-(pyrimidin-5-yl)-2H-chromen-2-one 
• 1428553-99-4 5,7-dimethyl-4-phenyl-6-(pyridin-4-yl)-2H-chromen-2-one 
• 1428553-85-8 6-(2-methoxyphenyl)-5,7-dimethyl-4-phenyl-2H-chromen-2-one 
• 1428553-86-9 6-(3-methoxyphenyl)-5,7-dimethyl-4-phenyl-2H-chromen-2-one 
• 1428553-93-8 6-(2-chlorophenyl)-5,7-dimethyl-4-phenyl-2H-chromen-2-one 
• 1428553-91-6 6-(4-chlorophenyl)-5,7-dimethyl-4-phenyl-2H-chromen-2-one 
• 1428553-96-1 5,7-dimethyl-4-phenyl-6-(3-(trifluoromethyl)phenyl)-2H-chromen-2-one 
• 1428553-95-0 6-(3-fluorophenyl)-5,7-dimethyl-4-phenyl-2H-chromen-2-one 
• 958751-28-5 C₂₄H₂₀O₃ 
• 1428553-97-2 6-(4-(1-hydroxyethyl)phenyl)-5,7-dimethyl-4-phenyl-2H-chromen-2-one 
• 1428553-74-5 6-(4-((hexylamino)methyl)phenyl)-5,7-dimethyl-4-phenyl-2H-chromen-2-one 

Relevant academic research and scientific papers

Compounds for the treatment of mycobacterial infections

The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:

COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS

The invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt, ester or prodrug thereof and further relates to the use of a compound of Formula (I) for the treatment of a bacterial infection, in particular, mycobacterial infection. The compounds of the invention can be used for anti-mycobacterial activity against clinically sensitive as well as resistant strains of Mycobacterium tuberculosis.

Synthesis and structure-activity relationships of phenyl-substituted coumarins with anti-tubercular activity that target FadD32

In an effort to develop new and potent agents for therapy against tuberculosis, a high-throughput screen was performed against Mycobacterium tuberculosis strain H37Rv. Two 6-aryl-5,7-dimethyl-4-phenylcoumarin compounds 1a and 1b were found with modest activity. A series of coumarin derivatives were synthesized to improve potency and to investigate the structure-activity relationship of the series. Among them, compounds 1o and 2d showed improved activity with IC90 of 2 μM and 0.5 μM, respectively. Further optimization provided compound 3b with better physiochemical properties with IC90 0.4 μM which had activity in a mouse model of infection. The role of the conformation of the 4- and 6-aryl substituents is also described.

Sequential Pd(II)-Pd(0) catalysis for the rapid synthesis of coumarins

Electrophilic palladium-catalyzed cycloisomerization of brominated aryl propiolates produces brominated coumarins. The brominated coumarins can be diversified by reduction of the Pd(II) catalyst to Pd(0) followed by Suzuki, Sonogashira, Heck, or Hartwig-B

New Method for Preparation of Coumarins and Quinolinones via Pd-Catalyzed Intramolecular Hydroarylation of C-C Triple Bonds

A new and general method has been developed for preparation of coumarins and quinolinones by intramolecular hydroarylation of alkynes. Various aryl alkynoates and alkynanilides undergo fast intramolecular reaction at room temperature in the presence of a